The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Anthrax Vaccines Market Research Report 2024
Synopsis
Anthrax is a serious disease that can affect both animals and humans. It is caused by bacteria called Bacillus anthracis. People can get anthrax from contact with infected animals, wool, meat, or hides.Anthrax vaccine protects against anthrax disease. Anthrax vaccine was licensed in 1970.Based on limited but sound evidence, the vaccine protects against both cutaneous (skin) and inhalation anthrax.
The global Anthrax Vaccines market was valued at US$ 655 million in 2023 and is anticipated to reach US$ 1100.3 million by 2030, witnessing a CAGR of 7.6% during the forecast period 2024-2030.
Global Anthrax Vaccines key players include Emergent BioSolutions, Merial, Merck, Zoetis, PharmAthene, etc. Global top five players hold a share about 70%.
North America is the largest market, with a share about 60%, followed by Latin America and Europe, having a total share about 20 percent.
In terms of product, Live Vaccines is the largest segment, with a share about 95%. And in terms of application, the largest application is Human Use, followed by Animal Use.
This report aims to provide a comprehensive presentation of the global market for Anthrax Vaccines, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Anthrax Vaccines.
Report Scope
The Anthrax Vaccines market size, estimations, and forecasts are provided in terms of sales volume (M Doses) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Anthrax Vaccines market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Anthrax Vaccines manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Emergent BioSolutions
Merial
Merck
Zoetis
Bayer Sanidad Animal
Colorado Serum
PharmAthene
Tiankang
Biogénesis-Bago
CAVAC
Rosenbusch
Agrovet
Vecol
CVCRI
IVPM
Prondil
CDV
Indian Immunologicals
Botswana Vaccine Institute
Ceva Santé Animale
Intervac
JOVAC
Segment by Type
Live Vaccines
Cell free PA Vaccines
Segment by Application
Human Use
Animal Use
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Anthrax Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Anthrax Vaccines in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Anthrax is a serious disease that can affect both animals and humans. It is caused by bacteria called Bacillus anthracis. People can get anthrax from contact with infected animals, wool, meat, or hides.Anthrax vaccine protects against anthrax disease. Anthrax vaccine was licensed in 1970.Based on limited but sound evidence, the vaccine protects against both cutaneous (skin) and inhalation anthrax.
The global Anthrax Vaccines market was valued at US$ 655 million in 2023 and is anticipated to reach US$ 1100.3 million by 2030, witnessing a CAGR of 7.6% during the forecast period 2024-2030.
Global Anthrax Vaccines key players include Emergent BioSolutions, Merial, Merck, Zoetis, PharmAthene, etc. Global top five players hold a share about 70%.
North America is the largest market, with a share about 60%, followed by Latin America and Europe, having a total share about 20 percent.
In terms of product, Live Vaccines is the largest segment, with a share about 95%. And in terms of application, the largest application is Human Use, followed by Animal Use.
This report aims to provide a comprehensive presentation of the global market for Anthrax Vaccines, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Anthrax Vaccines.
Report Scope
The Anthrax Vaccines market size, estimations, and forecasts are provided in terms of sales volume (M Doses) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Anthrax Vaccines market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Anthrax Vaccines manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Emergent BioSolutions
Merial
Merck
Zoetis
Bayer Sanidad Animal
Colorado Serum
PharmAthene
Tiankang
Biogénesis-Bago
CAVAC
Rosenbusch
Agrovet
Vecol
CVCRI
IVPM
Prondil
CDV
Indian Immunologicals
Botswana Vaccine Institute
Ceva Santé Animale
Intervac
JOVAC
Segment by Type
Live Vaccines
Cell free PA Vaccines
Segment by Application
Human Use
Animal Use
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Anthrax Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Anthrax Vaccines in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Anthrax Vaccines Market Overview
1.1 Product Overview and Scope of Anthrax Vaccines
1.2 Anthrax Vaccines Segment by Type
1.2.1 Global Anthrax Vaccines Market Value Comparison by Type (2024-2030)
1.2.2 Live Vaccines
1.2.3 Cell free PA Vaccines
1.3 Anthrax Vaccines Segment by Application
1.3.1 Global Anthrax Vaccines Market Value by Application: (2024-2030)
1.3.2 Human Use
1.3.3 Animal Use
1.4 Global Anthrax Vaccines Market Size Estimates and Forecasts
1.4.1 Global Anthrax Vaccines Revenue 2019-2030
1.4.2 Global Anthrax Vaccines Sales 2019-2030
1.4.3 Global Anthrax Vaccines Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Anthrax Vaccines Market Competition by Manufacturers
2.1 Global Anthrax Vaccines Sales Market Share by Manufacturers (2019-2024)
2.2 Global Anthrax Vaccines Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Anthrax Vaccines Average Price by Manufacturers (2019-2024)
2.4 Global Anthrax Vaccines Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Anthrax Vaccines, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Anthrax Vaccines, Product Type & Application
2.7 Anthrax Vaccines Market Competitive Situation and Trends
2.7.1 Anthrax Vaccines Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Anthrax Vaccines Players Market Share by Revenue
2.7.3 Global Anthrax Vaccines Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Anthrax Vaccines Retrospective Market Scenario by Region
3.1 Global Anthrax Vaccines Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Anthrax Vaccines Global Anthrax Vaccines Sales by Region: 2019-2030
3.2.1 Global Anthrax Vaccines Sales by Region: 2019-2024
3.2.2 Global Anthrax Vaccines Sales by Region: 2025-2030
3.3 Global Anthrax Vaccines Global Anthrax Vaccines Revenue by Region: 2019-2030
3.3.1 Global Anthrax Vaccines Revenue by Region: 2019-2024
3.3.2 Global Anthrax Vaccines Revenue by Region: 2025-2030
3.4 North America Anthrax Vaccines Market Facts & Figures by Country
3.4.1 North America Anthrax Vaccines Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Anthrax Vaccines Sales by Country (2019-2030)
3.4.3 North America Anthrax Vaccines Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Anthrax Vaccines Market Facts & Figures by Country
3.5.1 Europe Anthrax Vaccines Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Anthrax Vaccines Sales by Country (2019-2030)
3.5.3 Europe Anthrax Vaccines Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Anthrax Vaccines Market Facts & Figures by Country
3.6.1 Asia Pacific Anthrax Vaccines Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Anthrax Vaccines Sales by Country (2019-2030)
3.6.3 Asia Pacific Anthrax Vaccines Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Anthrax Vaccines Market Facts & Figures by Country
3.7.1 Latin America Anthrax Vaccines Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Anthrax Vaccines Sales by Country (2019-2030)
3.7.3 Latin America Anthrax Vaccines Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Anthrax Vaccines Market Facts & Figures by Country
3.8.1 Middle East and Africa Anthrax Vaccines Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Anthrax Vaccines Sales by Country (2019-2030)
3.8.3 Middle East and Africa Anthrax Vaccines Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Anthrax Vaccines Sales by Type (2019-2030)
4.1.1 Global Anthrax Vaccines Sales by Type (2019-2024)
4.1.2 Global Anthrax Vaccines Sales by Type (2025-2030)
4.1.3 Global Anthrax Vaccines Sales Market Share by Type (2019-2030)
4.2 Global Anthrax Vaccines Revenue by Type (2019-2030)
4.2.1 Global Anthrax Vaccines Revenue by Type (2019-2024)
4.2.2 Global Anthrax Vaccines Revenue by Type (2025-2030)
4.2.3 Global Anthrax Vaccines Revenue Market Share by Type (2019-2030)
4.3 Global Anthrax Vaccines Price by Type (2019-2030)
5 Segment by Application
5.1 Global Anthrax Vaccines Sales by Application (2019-2030)
5.1.1 Global Anthrax Vaccines Sales by Application (2019-2024)
5.1.2 Global Anthrax Vaccines Sales by Application (2025-2030)
5.1.3 Global Anthrax Vaccines Sales Market Share by Application (2019-2030)
5.2 Global Anthrax Vaccines Revenue by Application (2019-2030)
5.2.1 Global Anthrax Vaccines Revenue by Application (2019-2024)
5.2.2 Global Anthrax Vaccines Revenue by Application (2025-2030)
5.2.3 Global Anthrax Vaccines Revenue Market Share by Application (2019-2030)
5.3 Global Anthrax Vaccines Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Emergent BioSolutions
6.1.1 Emergent BioSolutions Corporation Information
6.1.2 Emergent BioSolutions Description and Business Overview
6.1.3 Emergent BioSolutions Anthrax Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Emergent BioSolutions Anthrax Vaccines Product Portfolio
6.1.5 Emergent BioSolutions Recent Developments/Updates
6.2 Merial
6.2.1 Merial Corporation Information
6.2.2 Merial Description and Business Overview
6.2.3 Merial Anthrax Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Merial Anthrax Vaccines Product Portfolio
6.2.5 Merial Recent Developments/Updates
6.3 Merck
6.3.1 Merck Corporation Information
6.3.2 Merck Description and Business Overview
6.3.3 Merck Anthrax Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Merck Anthrax Vaccines Product Portfolio
6.3.5 Merck Recent Developments/Updates
6.4 Zoetis
6.4.1 Zoetis Corporation Information
6.4.2 Zoetis Description and Business Overview
6.4.3 Zoetis Anthrax Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Zoetis Anthrax Vaccines Product Portfolio
6.4.5 Zoetis Recent Developments/Updates
6.5 Bayer Sanidad Animal
6.5.1 Bayer Sanidad Animal Corporation Information
6.5.2 Bayer Sanidad Animal Description and Business Overview
6.5.3 Bayer Sanidad Animal Anthrax Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Bayer Sanidad Animal Anthrax Vaccines Product Portfolio
6.5.5 Bayer Sanidad Animal Recent Developments/Updates
6.6 Colorado Serum
6.6.1 Colorado Serum Corporation Information
6.6.2 Colorado Serum Description and Business Overview
6.6.3 Colorado Serum Anthrax Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Colorado Serum Anthrax Vaccines Product Portfolio
6.6.5 Colorado Serum Recent Developments/Updates
6.7 PharmAthene
6.6.1 PharmAthene Corporation Information
6.6.2 PharmAthene Description and Business Overview
6.6.3 PharmAthene Anthrax Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.4.4 PharmAthene Anthrax Vaccines Product Portfolio
6.7.5 PharmAthene Recent Developments/Updates
6.8 Tiankang
6.8.1 Tiankang Corporation Information
6.8.2 Tiankang Description and Business Overview
6.8.3 Tiankang Anthrax Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Tiankang Anthrax Vaccines Product Portfolio
6.8.5 Tiankang Recent Developments/Updates
6.9 Biogénesis-Bago
6.9.1 Biogénesis-Bago Corporation Information
6.9.2 Biogénesis-Bago Description and Business Overview
6.9.3 Biogénesis-Bago Anthrax Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Biogénesis-Bago Anthrax Vaccines Product Portfolio
6.9.5 Biogénesis-Bago Recent Developments/Updates
6.10 CAVAC
6.10.1 CAVAC Corporation Information
6.10.2 CAVAC Description and Business Overview
6.10.3 CAVAC Anthrax Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.10.4 CAVAC Anthrax Vaccines Product Portfolio
6.10.5 CAVAC Recent Developments/Updates
6.11 Rosenbusch
6.11.1 Rosenbusch Corporation Information
6.11.2 Rosenbusch Anthrax Vaccines Description and Business Overview
6.11.3 Rosenbusch Anthrax Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Rosenbusch Anthrax Vaccines Product Portfolio
6.11.5 Rosenbusch Recent Developments/Updates
6.12 Agrovet
6.12.1 Agrovet Corporation Information
6.12.2 Agrovet Anthrax Vaccines Description and Business Overview
6.12.3 Agrovet Anthrax Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Agrovet Anthrax Vaccines Product Portfolio
6.12.5 Agrovet Recent Developments/Updates
6.13 Vecol
6.13.1 Vecol Corporation Information
6.13.2 Vecol Anthrax Vaccines Description and Business Overview
6.13.3 Vecol Anthrax Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Vecol Anthrax Vaccines Product Portfolio
6.13.5 Vecol Recent Developments/Updates
6.14 CVCRI
6.14.1 CVCRI Corporation Information
6.14.2 CVCRI Anthrax Vaccines Description and Business Overview
6.14.3 CVCRI Anthrax Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.14.4 CVCRI Anthrax Vaccines Product Portfolio
6.14.5 CVCRI Recent Developments/Updates
6.15 IVPM
6.15.1 IVPM Corporation Information
6.15.2 IVPM Anthrax Vaccines Description and Business Overview
6.15.3 IVPM Anthrax Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.15.4 IVPM Anthrax Vaccines Product Portfolio
6.15.5 IVPM Recent Developments/Updates
6.16 Prondil
6.16.1 Prondil Corporation Information
6.16.2 Prondil Anthrax Vaccines Description and Business Overview
6.16.3 Prondil Anthrax Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.16.4 Prondil Anthrax Vaccines Product Portfolio
6.16.5 Prondil Recent Developments/Updates
6.17 CDV
6.17.1 CDV Corporation Information
6.17.2 CDV Anthrax Vaccines Description and Business Overview
6.17.3 CDV Anthrax Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.17.4 CDV Anthrax Vaccines Product Portfolio
6.17.5 CDV Recent Developments/Updates
6.18 Indian Immunologicals
6.18.1 Indian Immunologicals Corporation Information
6.18.2 Indian Immunologicals Anthrax Vaccines Description and Business Overview
6.18.3 Indian Immunologicals Anthrax Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.18.4 Indian Immunologicals Anthrax Vaccines Product Portfolio
6.18.5 Indian Immunologicals Recent Developments/Updates
6.19 Botswana Vaccine Institute
6.19.1 Botswana Vaccine Institute Corporation Information
6.19.2 Botswana Vaccine Institute Anthrax Vaccines Description and Business Overview
6.19.3 Botswana Vaccine Institute Anthrax Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.19.4 Botswana Vaccine Institute Anthrax Vaccines Product Portfolio
6.19.5 Botswana Vaccine Institute Recent Developments/Updates
6.20 Ceva Santé Animale
6.20.1 Ceva Santé Animale Corporation Information
6.20.2 Ceva Santé Animale Anthrax Vaccines Description and Business Overview
6.20.3 Ceva Santé Animale Anthrax Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.20.4 Ceva Santé Animale Anthrax Vaccines Product Portfolio
6.20.5 Ceva Santé Animale Recent Developments/Updates
6.21 Intervac
6.21.1 Intervac Corporation Information
6.21.2 Intervac Anthrax Vaccines Description and Business Overview
6.21.3 Intervac Anthrax Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.21.4 Intervac Anthrax Vaccines Product Portfolio
6.21.5 Intervac Recent Developments/Updates
6.22 JOVAC
6.22.1 JOVAC Corporation Information
6.22.2 JOVAC Anthrax Vaccines Description and Business Overview
6.22.3 JOVAC Anthrax Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.22.4 JOVAC Anthrax Vaccines Product Portfolio
6.22.5 JOVAC Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Anthrax Vaccines Industry Chain Analysis
7.2 Anthrax Vaccines Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Anthrax Vaccines Production Mode & Process
7.4 Anthrax Vaccines Sales and Marketing
7.4.1 Anthrax Vaccines Sales Channels
7.4.2 Anthrax Vaccines Distributors
7.5 Anthrax Vaccines Customers
8 Anthrax Vaccines Market Dynamics
8.1 Anthrax Vaccines Industry Trends
8.2 Anthrax Vaccines Market Drivers
8.3 Anthrax Vaccines Market Challenges
8.4 Anthrax Vaccines Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
